Researchers compared the combination therapy of guselkumab and golimumab (both from Janssen) for 12 weeks, followed by guselkumab monotherapy up to week 38, versus either agent as monotherapy for ...

Simponi and Simponi Aria contain the active drug golimumab, which is a biologic drug. A biologic medication is made from parts of living cells. Simponi and Simponi Aria aren’t available in ...

The US Food and Drug Administration (FDA) has approved golimumab (Simponi Aria, Janssen Biotech) for adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Golimumab ...

Patients were randomized 2:1 to receive a 30 (+/- 10) minute I.V. infusion of golimumab 2 mg/kg or placebo at weeks 0, 4, and then every 8 weeks; in both treatment arms, methotrexate was taken.

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of golimumab, having considered evidence on the nature of psoriatic arthritis and the value placed on the ...

Simponi and Simponi Aria (golimumab) can cause mild to serious side effects. A more common side effect includes upper respiratory infection. If side effects from the drug become difficult to ...

PARIS, June 11 -- Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg and weekly methotrexate (MTX ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of golimumab, having considered evidence on the nature of rheumatoid arthritis and the value placed on the ...

Alvotech’s proposed biosimilar to Simponi ® and Simponi Aria ® (golimumab). Alvotech is the first company to announce positive topline results of a clinical trial using a proposed biosimilar ...

These are the first U.S. BLA filing acceptances announced for a biosimilar candidate to golimumab. The FDA review process for these applications is anticipated to be completed in the fourth ...